1. Home
  2. FF vs ALXO Comparison

FF vs ALXO Comparison

Compare FF & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FutureFuel Corp.

FF

FutureFuel Corp.

HOLD

Current Price

$4.11

Market Cap

212.3M

Sector

Industrials

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.04

Market Cap

240.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FF
ALXO
Founded
N/A
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
212.3M
240.8M
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
FF
ALXO
Price
$4.11
$2.04
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$3.50
AVG Volume (30 Days)
376.0K
1.0M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
5.32%
N/A
EPS Growth
N/A
26.36
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.09
$0.41
52 Week High
$5.12
$2.66

Technical Indicators

Market Signals
Indicator
FF
ALXO
Relative Strength Index (RSI) 41.15 57.37
Support Level $3.78 $1.99
Resistance Level $4.13 $2.30
Average True Range (ATR) 0.24 0.17
MACD -0.02 0.05
Stochastic Oscillator 4.19 76.30

Price Performance

Historical Comparison
FF
ALXO

About FF FutureFuel Corp.

FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: